REPL:NSD-Replimune Group Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 11.53

Change

+0.33 (+2.95)%

Market Cap

USD 0.96B

Volume

0.50M

Analyst Target

USD 30.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.79 (+0.93%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+3.29 (+0.45%)

USD 78.92B
ARGX argenx NV ADR

+0.64 (+0.10%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+4.60 (+1.95%)

USD 30.22B
MRNA Moderna Inc

-4.36 (-9.17%)

USD 18.29B
UTHR United Therapeutics Corporatio..

+4.28 (+1.18%)

USD 15.91B
RPRX Royalty Pharma Plc

+0.16 (+0.61%)

USD 15.05B
SMMT Summit Therapeutics PLC

+0.66 (+3.63%)

USD 13.43B
INCY Incyte Corporation

-0.06 (-0.08%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.48 (+0.71%)

USD 12.74B

ETFs Containing REPL

CNCR Loncar Cancer Immunothera.. 1.96 % 0.79 %

-0.39 (-2.99%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.79% 25% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.79% 25% F 18% F
Trailing 12 Months  
Capital Gain 27.83% 77% C+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.83% 77% C+ 78% C+
Trailing 5 Years  
Capital Gain -35.12% 66% D+ 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.12% 66% D+ 30% F
Average Annual (5 Year Horizon)  
Capital Gain -2.83% 43% F 31% F
Dividend Return -2.83% 43% F 28% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 64.64% 54% F 30% F
Risk Adjusted Return -4.38% 43% F 31% F
Market Capitalization 0.96B 81% B- 71% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector